What is Perspective Therapeutics's revenue?

Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.

Is Perspective Therapeutics profitable?

Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.

What are Perspective Therapeutics's profit margins?

Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.

What is Perspective Therapeutics's earnings per share?

Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.

Where does Perspective Therapeutics's income statement data come from?

Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Perspective Therapeutics CATX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$84.22M+102%	$41.64M+95.4%	$21.31M+725%	$2.58M—
General and administrative	$30.23M+13.6%	$26.61M+26.3%	$21.06M+218%	$6.62M+41.1%
Goodwill impairment	$0—	——	$0—	——
Other operating expenses	$114.45M+23.9%	$92.34M+118%	$42.38M+253%	$12.01M+40.2%
Total operating expenses	$114.45M+23.9%	$92.34M+118%	$42.38M+253%	$12.01M+40.2%
Operating income	-$113.56M-25.0%	-$90.89M-122%	-$40.94M-432%	-$7.69M—
Interest income	$8.11M-22.8%	$10.52M+1,026%	$934K—	——
Other income (expense), net	$9.14M-12.6%	$10.46M+1,153%	$835K—	——
Income before income taxes	-$104.43M-29.8%	-$80.43M-101%	-$40.11M—	——
Net income	-$103.12M-30.1%	-$79.28M-70.5%	-$46.51M-521%	-$7.49M-32.5%
Income from discontinued operations	$514K+154%	-$949K+89.5%	-$9.05M—	——
Diluted earnings per share	-$1.40-12.0%	-$1.25+25.6%	-$1.68—	——
Basic earnings per share	-$1.40-12.0%	-$1.25+25.6%	-$1.68-3,260%	-$0.050.0%
Weighted-average shares, diluted	294.7M+17.3%	251.2M-19.3%	311.4M—	——
Weighted-average shares, basic	294.7M+17.3%	251.2M-19.3%	311.4M-45.2%	568.1M+3.7%
Interest And Other Expense	$376K—	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$102.96M-29.8%	-$79.33M-70.6%	-$46.51M—	——
Goodwill impairment losses	$0—	——	$0—	——
Net unrealized gains (losses) on securities still held	$165K+424%	-$51K—	$0—	——
Other Nonoperating Income	$1.4M—	$0—	——	——
Revenue from contracts outside the scope of ASC Topic 606	$884K-39.2%	$1.45M+1.4%	$1.43M—	——
EBIT	-$113.56M-25.0%	-$90.89M-122%	-$40.94M-432%	-$7.69M—
EBITDA	-$110.31M-24.5%	-$88.58M-122%	-$39.96M—	——
EBITDA	-$110.31M-24.5%	-$88.58M-122%	-$39.96M—	——
EBIT	-$113.56M-25.0%	-$90.89M-122%	-$40.94M-432%	-$7.69M—

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Perspective Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Perspective Therapeutics's revenue?: Perspective Therapeutics (CATX) generated $10.0M in revenue over the trailing twelve months, up 0.5% year over year.
Is Perspective Therapeutics profitable?: Perspective Therapeutics is not currently profitable: it reported a net loss of $111.1M over the trailing twelve months, a -218.4% net margin.
What are Perspective Therapeutics's profit margins?: Gross margin is 33.1% and operating margin is -292.7%, with a -218.4% net margin.
What is Perspective Therapeutics's earnings per share?: Perspective Therapeutics's diluted EPS over the trailing twelve months is $-1.40.
Where does Perspective Therapeutics's income statement data come from?: Every line is extracted from Perspective Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.